Physician profile
Max E Seaton
NPI 1184980260
$9,296.02
in general payments reported to CMS, 2019-2025
52 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.77 · 2022: $7,643 · 2023: $581 · 2024: $497 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,073.20 | 2022 | |
| Janssen Biotech, INC. | $203.61 | 2021-2024 | Erleada, Darzalex, Talvey |
| Lilly USA, LLC | $117.55 | 2022-2025 | Verzenio |
| Astrazeneca Pharmaceuticals Lp | $110.27 | 2024-2025 | Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $108.18 | 2023-2025 | |
| Genentech USA, INC. | $104.92 | 2022-2025 | Tecentriq, Rozlytrek, Alecensa |
| Incyte Corporation | $87.15 | 2022-2023 | Jakafi |
| Eisai INC. | $86.96 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $83.30 | 2022-2024 | Keytruda, Lynparza |
| Regeneron Healthcare Solutions, INC. | $67.81 | 2023-2024 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $66.00 | 2022-2024 | |
| Morphosys, US INC. | $56.48 | 2021-2023 | Monjuvi |
| Myriad Genetic Laboratories, INC. | $56.40 | 2022-2023 | Myrisk |
| Iovance Biotherapeutics, INC. | $55.27 | 2025 | Amtagvi |
| Seagen INC. | $54.18 | 2022-2023 | Tukysa, Padcev |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Seaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.